Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Classical hematology 2

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 2Leukemia, Biphenotypic, Acute 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Patient Preference 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1GATA2 Deficiency 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Whole-Body Irradiation 55Busulfan 54Antilymphocyte Serum 47Cyclosporine 45Methotrexate 38fludarabine 37Filgrastim 37Melphalan 32Radiotherapy 27Cytarabine 27Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Azacitidine 18Sirolimus 15Granulocyte Colony-Stimulating Factor 15Flow Cytometry 14Cyclosporins 14thymoglobulin 13Specimen Handling 13Alemtuzumab 13Biopsy 12venetoclax 10Thiotepa 10Decitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡